Nama's AI scorecard currently rates AbbVie Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is ABBV's P/E ratio?

AbbVie trades at a trailing price-to-earnings ratio of 22.7.

When does ABBV report earnings?

AbbVie's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $3.88.

What is the ABBV price target?

The median analyst price target from 26 analysts is $314.00, with a range of $237.00 – $350.00.

Is ABBV Shariah compliant?

Nama's AAOIFI-style screen reads AbbVie as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Does ABBV pay a dividend?

Yes — AbbVie's dividend yield is 2.4%.

Nama Insights

AbbVie (ABBV)

Healthcare · Drug Manufacturers General · NYSE

S&P 500

AbbVie (ABBV) is a Healthcare company in the Drug Manufacturers General industry. It has a market capitalization of $514.92B, a trailing price-to-earnings ratio of 22.7 and a free-cash-flow yield of 3.5%. Over the most recent reported fiscal year, revenue grew 8.6% and free cash flow per share fell 0.1%. Nama's AI scorecard rates it Buy, 6.3 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Buy · 6.3/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Rising · +23.9% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-3.8%

How far the last close sits under the highest price of the past five years.

Market cap	$514.92B
Trailing P/E	22.7
Price / book	—
Price / sales	7.8
FCF yield	3.5%
Dividend yield	2.4%
Gross margin	71.5%
Operating margin	33.9%
Net margin	9.8%
Revenue growth (YoY)	+8.6%
Revenue growth (3-yr annual)	+1.8%
EPS growth (YoY)	-1.2%
FCF/share growth (YoY)	-0.1%
Beta	0.2
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers General

ABBV earnings

Next report: Feb 3, 2027 (Q4 2026, EPS estimate $3.88). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Oct 30, 2026	$3.82	$3.76	+1.6%	$17.40B
Q2 2026	Jul 31, 2026	$3.65	$3.61	+1.1%	$16.99B
Q1 2026	Apr 29, 2026	$2.65	$2.67	-0.8%	$15.00B
Q4 2025	Feb 4, 2026	$2.71	$2.65	+2.3%	$16.62B

ABBV analyst price target

Median target $314.00 from 26 analysts, ranging $237.00 – $350.00.

Drug Manufacturers General peers

Ticker	Company	Market cap	P/E
LLY	Eli Lilly	$1.21T	42.4
JNJ	Johnson & Johnson	$664.95B	25.9
MRK	Merck	$361.73B	47.0
NVS	Novartis	$307.00B	19.0
AZN	AstraZeneca	$289.14B	38.8
AMGN	Amgen	$249.05B	19.9
GILD	Gilead Sciences	$207.00B	—
NVO	Novo Nordisk A/S	$177.74B	11.0

Explore live ABBV data on Nama Insights →

Recent Congressional trades

AbbVie trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Pete Sessions	House	Sell	$15,001 - $50,000	Sep 18, 2026
Alan Armstrong	Senate	Buy	$15,001 - $50,000	Jul 21, 2026
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jun 3, 2026
Julie Johnson	House	Sell	$1,001 - $15,000	Jan 15, 2026
Julia Letlow	House	Buy	$1,001 - $15,000	Jan 13, 2026
Julia Letlow	House	Buy	$1,001 - $15,000	Jan 13, 2026
Julie Johnson	House	Sell	$1,001 - $15,000	Dec 11, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Nov 21, 2025
Julie Johnson	House	Sell	$1,001 - $15,000	Sep 11, 2025
Ritchie John Torres	House	Buy	$1,001 - $15,000	Aug 20, 2025
Marjorie Taylor Greene	House	Buy	$1,001 - $15,000	Aug 15, 2025

ABBV FAQ

Is ABBV a buy?: Nama's AI scorecard currently rates AbbVie Buy (6.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is ABBV's P/E ratio?: AbbVie trades at a trailing price-to-earnings ratio of 22.7.
When does ABBV report earnings?: AbbVie's next scheduled report is on Feb 3, 2027. Analysts expect EPS of $3.88.
What is the ABBV price target?: The median analyst price target from 26 analysts is $314.00, with a range of $237.00 – $350.00.
Is ABBV Shariah compliant?: Nama's AAOIFI-style screen reads AbbVie as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.
Does ABBV pay a dividend?: Yes — AbbVie's dividend yield is 2.4%.